Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -44771.83% is 111% below its 5-year average of -21266.15%, near the high end of its 5-year range (-250321.79%–0.00%).
2.44% below its 12-month average of -43705.24%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -28012.46%.
NET PROFIT MARGIN
-44771.83%
NET PROFIT MARGIN AVG TTM
-43705.24%
NET PROFIT MARGIN AVG 3Y
-32872.29%
NET PROFIT MARGIN AVG 5Y
-21266.15%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2.44%
CURRENT VS 3Y AVG
-36.20%
CURRENT VS 5Y AVG
-110.53%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Cardio Diagnostics Holdings, Inc.
Market Cap
$6.10M
Net Profit Margin
-44771.83%
TTM Avg
-43705.24%
3Y Avg
-32872.29%
5Y Avg
-21266.15%
Market Cap
$6.10M
Net Profit Margin
-534.27%
TTM Avg
-983.65%
3Y Avg
-1060.24%
5Y Avg
-924.37%
Market Cap
$6.09M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-86.55%
Market Cap
$6.03M
Net Profit Margin
-9366.75%
TTM Avg
-6298.14%
3Y Avg
-3910.26%
5Y Avg
-3305.87%
Market Cap
$6.34M
Net Profit Margin
-84.79%
TTM Avg
-89.20%
3Y Avg
-105.63%
5Y Avg
-91.66%
Market Cap
$6.44M
Net Profit Margin
-1084.23%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.63M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.72M
Net Profit Margin
-611.47%
TTM Avg
-627.26%
3Y Avg
-917.71%
5Y Avg
-6297.45%
Market Cap
$6.74M
Net Profit Margin
-10978.48%
TTM Avg
-12422.83%
3Y Avg
-10763.38%
5Y Avg
-10131.90%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | $6.10M | -44771.83% | -43705.24% | -32872.29% | -21266.15% |
| Femasys Inc. (FEMY)vs › | $6.10M | -534.27% | -983.65% | -1060.24% | -924.37% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | 0.00% | 0.00% | 0.00% | -86.55% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | -9366.75% | -6298.14% | -3910.26% | -3305.87% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | -84.79% | -89.20% | -105.63% | -91.66% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | -1084.23% | 0.00% | 0.00% | 0.00% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -611.47% | -627.26% | -917.71% | -6297.45% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -10978.48% | -12422.83% | -10763.38% | -10131.90% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-43737.5%
Net Profit Margin
-44771.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -28012.46% |
| 2026-03-31 | -66722.31% |
| 2025-12-31 | -41219.92% |
| 2025-09-30 | -60053.80% |
| 2025-06-30 | -22517.71% |
| 2025-03-31 | -173942.98% |
| 2024-12-31 | -33672.61% |
| 2024-09-30 | -21467.57% |
| 2024-06-30 | -16365.88% |
| 2024-03-31 | -26140.03% |
| 2023-12-31 | -26156.85% |
| 2023-09-30 | -19266.02% |
| 2023-06-30 | -233211.88% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -250321.79% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | -21195.45% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
